Therefore, contemporary guidelines provide a Class IIa recommendation for the use of ACE inhibitors or ARBs and beta-blockers as primary prevention therapy in high-risk cancer patients receiving oncological therapies that may increase the risk of HF [9]. This evidence concerns the gene ACE and cancer.